Results 61 to 70 of about 131,053 (266)

Pharmacotherapy of osteoporosis.

Folia Pharmacologica Japonica, 2002
Osteoporosis with increased risk of bone fracture is a disabling syndrome that naturally occurs as long as one ages and moves on two legs. Recent progress in bone cell biology has shed light on the mechanisms underlying the anti-osteoporotic properties of drugs that have been in use for a long time, providing a fresh stage for novel pharmacotherapies ...
openaire   +3 more sources

Pharmacotherapy of Asthma [PDF]

American Journal of Pharmaceutical Education, 2007
The pharmacotherapy of asthma is a complex and evolving topic. A detailed understanding of the pathophysiologic processes involved in the asthmatic response forms the basis for understanding the actions of drugs used to treat this condition. Likewise, a solid comprehension of the medicinal chemistry and pharmacologic properties of the numerous agents ...
openaire   +2 more sources

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Optimizing pharmacogenomic clinical decision support: a usability study of epic’s Genomic-Indicators

BMC Pharmacology and Toxicology
Background Pharmacogenomic (PGx)-guided therapy has demonstrated improved medication-related outcomes and reduced healthcare costs. Interruptive clinical decision support (CDS) alerts are crucial in providing guidance to providers in PGx-informed ...
Je-Won J. Hong, Bradley T. Hall, Syed Azeem, Dean A. Jacobs, Grace C. Hogan, Madeline L. Norris, Emily J. Cicali, Julio D. Duarte, Larisa H. Cavallari, Khoa A. Nguyen   +9 more
doaj   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Plasma Melanin-Concentrating Hormone in Childhood Obesity and Its Association with Metabolic Parameters: A Clinical Observational Study

Diabetes, Metabolic Syndrome and Obesity
Imre Leiter,1,&ast; Beáta Lelesz,1,&ast; Csaba Heged&udblac;s,1 József Németh,1 Beáta Pelles-Taskó,1 Gyula Ujlaki,1 Harjit Pal Bhattoa,2 Enik&odblac; Noémi Felszeghy,3 Szabolcs Lengyel,4 Dénes Páll,4 György Balla,3 Zoltán Szilvássy,1 Béla
Leiter I, Lelesz B, Hegedűs C, Németh J, Pelles-Taskó B, Ujlaki G, Bhattoa HP, Felszeghy EN, Lengyel S, Páll D, Balla G, Szilvássy Z, Juhász B, Kiss R   +13 more
doaj  

Pharmacotherapies for COPD

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2013
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled ...
Stan Ejiofor, Alice M. Turner
openaire   +4 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Impact of a genetic counseling requirement prior to genetic testing

BMC Health Services Research, 2018
Background Genetic counseling by a Genetic Counselor (GC) is a requirement prior to genetic testing for cancer susceptibility genes (GC-mandate policy) for some insurers.
David D. Stenehjem, Trang Au, Amy M. Sainski, Hillevi Bauer, Krystal Brown, Johnathan Lancaster, Vanessa Stevens, Diana I. Brixner   +7 more
doaj   +1 more source